RxDoctor Payments Data

Lisa Webb, MD

Neurology · Stratford, CTNPI 1063458800

Payments from drug & device makers

$16,194in general payments, 2019–2025

Across 900 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$2K
  • Novartis$1K
  • Teva Pharmaceuticals USA, Inc.$885
  • SK Life Science, Inc.$764
  • Amneal Pharmaceuticals LLC$725
  • plus $8K from 50 others

What the payments were for

  • Speaking & faculty fees$340%
  • Food & beverage$16,155100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)144$2,610
UCB, Inc.74$1,509
Novartis105$1,333
Teva Pharmaceuticals USA, Inc.50$885
SK Life Science, Inc.41$764
Amneal Pharmaceuticals LLC51$725
Acadia Pharmaceuticals Inc39$675
Biogen46$670
Eisai Inc.21$547
AstraZeneca26$497
Lilly USA, LLC24$461
Pfizer20$414
Amgen(2 entities)19$392
Argenx US, Inc.17$391
EMD Serono, Inc.22$361
Sanofi19$346
Bristol Myers Squibb15$332
Genentech USA, Inc.14$316
Supernus Pharmaceuticals, Inc.19$302
Lundbeck LLC12$294
Biohaven Pharmaceutical Holding Company Ltd.12$241
MDD US Operations, LLC15$236
Biohaven Pharmaceuticals, Inc.13$225
Neurocrine Biosciences, Inc.7$177
Avanir Pharmaceuticals, Inc.8$159
Otsuka America Pharmaceutical, Inc.7$138
Adamas Pharmaceuticals, Inc.7$131
Kyowa Kirin, Inc.7$110
Akcea Therapeutics, Inc.3$71
Alnylam Pharmaceuticals Inc.3$71
TG Therapeutics, Inc.2$64
Tris Pharma Inc3$56
Ironshore Pharmaceuticals Inc.3$50
E.r. Squibb & Sons, L.L.C.2$49
Octapharma USA, Inc.2$42
Avion Pharmaceuticals2$41
Sunovion Pharmaceuticals Inc.2$39
Tanabe Pharma America, Inc.2$38
CSL Behring2$37
Acorda Therapeutics, Inc2$34
Merz Pharmaceuticals, LLC1$33
Sumitomo Pharma America, Inc.2$31
Grifols USA, LLC2$27
Collegium Pharmaceutical, Inc.1$25
Upsher-smith Laboratories LLC1$25
Axsome Therapeutics, Inc.1$24
Idorsia Pharmaceuticals US Inc1$24
Jazz Pharmaceuticals Inc.1$23
Impel Pharmaceuticals Inc.1$23
Neurelis, Inc.1$23
Corium, LLC1$22
Adlon Therapeutics L.p.1$20
Cycle Pharmaceuticals Inc1$18
Assertio Therapeutics, Inc.1$17
Arbor Pharmaceuticals, Inc.1$14
GE HealthCare1$14

How this compares

$16,194 in reported general payments places this provider in the 70th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$227,666
Medicare patients
212
Services billed
18,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GlatopaGlatiramer Acetate16$41,549
BotoxOnabotulinumtoxina22$37,014
Nurtec OdtRimegepant Sulfate24$25,279
UbrelvyUbrogepant15$17,282
Levetiracetam82$3,815
Carbidopa-LevodopaCarbidopa/Levodopa77$3,763
Gabapentin136$3,061
Propranolol Hcl ErPropranolol Hcl49$2,416
Pyridostigmine Bromide15$2,131
Lacosamide37$2,104
Oxcarbazepine17$1,935
Lamotrigine ErLamotrigine13$1,610
Pregabalin32$1,430
Memantine Hcl33$1,169
Dalfampridine ErDalfampridine12$936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy$2,610$54,29637 claims
PfizerNurtec Odt$414$25,27924 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$725$2,13115 claims
Upsher-smith Laboratories LLCTopiramate$25$89331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 280 neurology providers in Connecticut.

Other neurology in Stratford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →